Cooper Companies Inc. experienced a sharp decline in pre-open trading as investors digested a string of disappointing developments tied to the company's latest quarterly results and strategic choices. The stock fell about 15.3% to $53.76 in pre-market activity, reflecting market reaction to a revenue shortfall, weakened forward guidance and the abrupt end of a months-long strategic review.
After the market close on Wednesday, the company disclosed fiscal third-quarter 2026 revenue of $1.07 billion, roughly $30 million below the $1.1 billion consensus among analysts. Adjusted earnings per share of $1.15 narrowly exceeded the $1.12 estimate, but investors focused on the topline miss and the outlook rather than the modest beat on adjusted EPS.
Management set revenue guidance for the fourth quarter in a range from $1.057 billion to $1.080 billion, which implies organic growth of 0% to 2%. That guidance sits well below the Street expectation of about $1.12 billion. Executives pointed to a reduction in U.S. channel inventory at CooperVision as the principal headwind, and indicated that this channel destocking would be a continuing drag into the fourth quarter.
In parallel with the earnings release, Cooper Companies announced that its board unanimously decided to retain CooperSurgical after completing the strategic review that was initiated in December 2025. The board concluded that the offers received from potential acquirers did not sufficiently reflect the division's value, a judgment that was influenced in part by the entrance of a new competitor into the non-hormonal IUD market.
Analysts moved quickly to reassess their ratings. Piper Sandler lowered its rating to Neutral from Overweight and cut its price target to $59 from $86, highlighting that this marked the fourth guidance reduction over the past two years. Baird also trimmed its view to Neutral from Outperform and reduced its target to $61 from $85, pointing to weak organic growth in Americas CooperVision and restrained prospects for margin expansion in the near term.
Market context offered little support for the stock on the news. Pre-market moves showed the S&P 500 and the Dow Jones slightly higher while the NASDAQ was marginally negative, indicating that the selloff in Cooper Companies was driven by company-specific issues rather than broader market weakness.
Management did present several positives alongside the disappointing outlook: the company expanded its share repurchase authorization to $3 billion and reported record quarterly free cash flow of $273 million. Despite these items, investors appeared more concerned about the combination of the revenue miss, a fourth consecutive guidance reduction, the decision not to divest CooperSurgical, and swift analyst downgrades.
Taken together, those catalysts helped push the stock toward its lowest levels in over a year in pre-open trading, underscoring how operational and strategic uncertainties can weigh on an otherwise cash-generative business.
Summary
Cooper Companies reported third-quarter revenue below analyst expectations and issued softer fourth-quarter revenue guidance, while the board opted not to sell CooperSurgical after a strategic review. Analyst downgrades followed, and the stock plunged in pre-market trading despite a $3 billion buyback authorization and record free cash flow.
- Key points:
- Quarterly revenue of $1.07 billion missed the $1.1 billion consensus; adjusted EPS of $1.15 beat $1.12.
- Q4 revenue guidance of $1.057 billion to $1.080 billion implies 0% to 2% organic growth, below the Street's ~ $1.12 billion expectation.
- Board unanimously decided to retain CooperSurgical following a strategic review; new competitor entry in the non-hormonal IUD market affected valuation perceptions.
- Sectors impacted: Healthcare equipment and supplies, medical devices, and the broader equities market for medical-device and specialty-healthcare names.
Risks and uncertainties
- The persistence of U.S. channel inventory reductions at CooperVision, which management identified as a headwind into the fourth quarter - this affects demand visibility in the medical devices/vision care sector.
- Limited near-term margin expansion for CooperVision amid weak organic growth in the Americas, a concern cited by analysts - this could constrain profitability expectations in the healthcare equipment market.
- Valuation and strategic outcomes for CooperSurgical remain uncertain for investors following the decision to retain the unit after offers were deemed insufficient - competitive dynamics in the non-hormonal IUD market were a factor.